Postepy Dermatologii I Alergologii最新文献

{"title":"Transformation of recurrent hidradenoma into a metastatic hidradenocarcinoma in a 31-year old female patient.","authors":"Zoran Terzić, Marinko Paunovic, Ana Popovic, Filip Vukmirovic, Miloš Bojić","doi":"10.5114/ada.2023.133588","DOIUrl":"10.5114/ada.2023.133588","url":null,"abstract":"","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809825/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skin biophysical parameters and serum dermokine levels in airline pilots: a comparative study with office workers.","authors":"Piercarlo Minoretti, Andrés S Santiago Sáez, Ángel F García Martín, Miryam Liańo Riera, Manuel Gómez Serrano, Enzo Emanuele","doi":"10.5114/ada.2023.132262","DOIUrl":"10.5114/ada.2023.132262","url":null,"abstract":"<p><strong>Introduction: </strong>Concerns are growing in the aviation industry about occupational skin diseases like malignant melanoma (MM) among airline pilots (APs), due to the unique working environment that exposes them to various skin stressors.</p><p><strong>Aim: </strong>To compare five skin biophysical parameters in a group of 40 male APs, each matched in terms of age and service tenure (minimum of 5 years) with a control group of 40 male office workers (OWs). Considering the potential role of dermokine (DMKN) in skin barrier dysfunction and the pathogenesis of MM, we further analyzed the serum levels of this molecule and correlated them with the measured skin parameters.</p><p><strong>Material and methods: </strong>Stratum corneum skin hydration, transepidermal water loss (TEWL), sebum content, erythema index (EI), and melanin index (MI) were quantified by non-invasive instruments in the cheek region. Serum DMKN levels were measured using a commercially available enzyme-linked immunosorbent assay kit.</p><p><strong>Results: </strong>Compared with OWs, the skin of APs exhibited a decrease in hydration levels in the stratum corneum, coinciding with a higher TEWL. However, there was no significant variance in sebum content between the groups. MI was notably higher in APs than in OWs, as was EI. In APs, serum DMKN levels were independently associated with MI (β = 0.56, <i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>We found a significant link between the profession of an airline pilot and changes in skin biophysical parameters. Further research into the interplay between serum DMKN levels and the risk of MM in APs is warranted.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809828/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selected hormone levels and lipid abnormalities in patients with <i>acne vulgaris</i>.","authors":"Weronika Szybiak, Michalina Jarzemska, Michał Kowalczyk, Anna Sadowska-Przytocka, Barbara Wiêckowska, Ryszard Żaba, Katarzyna Lacka","doi":"10.5114/ada.2023.133457","DOIUrl":"10.5114/ada.2023.133457","url":null,"abstract":"<p><strong>Introduction: </strong><i>Acne vulgaris</i> is one of the most common dermatological diseases. Hormonal imbalance affects the skin condition and results in the formation of <i>acne vulgaris</i> lesions.</p><p><strong>Aim: </strong>To evaluate serum levels of testosterone, prolactin, luteinizing hormone (LH), follicle-stimulating hormone (FSH), triglycerides (TG), and high-density lipoprotein (HDL) in patients with <i>acne vulgaris</i> and compare them to healthy population.</p><p><strong>Material and methods: </strong>Forty-one patients with <i>acne vulgaris</i> and 47 age- and body mass index (BMI)-matched controls were enrolled in the study.</p><p><strong>Results: </strong>The mean ± SD testosterone serum level in the study group was 0.45 ±1.03 ng/ml in females and 4.24 ±0.68 in males and in the control group 0.73 ±2.03 ng/ml and 5.3 ±1.3 ng/ml in females and males, respectively. The prolactin serum level was 16.73 ±8.02 ng/ml in the study group and in the control group 13.74 ±8.71 ng/ml (<i>p</i> = 0.011). The FSH serum level was 12.17 ±16.93 mIU/ml and 6.2 ±7.3 mIU/ml in the study and control groups, respectively (<i>p</i> = 0.0001), whereas LH serum levels were 18.44 ±19.71 mIU/ml and 11.26 ±8 mIU/ml, respectively (<i>p</i> = 0.2659). The HDL serum level was 65.63 ±15.67 mg/dl in the study group and 61.53 ±15.89 mg/dl in the control group (<i>p</i> = 0.219), and TG levels were 175.29 ±82.15 mg/dl and 87.32 ±30.64 mg/dl, respectively (<i>p</i> < 0.00001).</p><p><strong>Conclusions: </strong>Our study demonstrates, that hormonal and lipid imbalance could be linked to <i>acne vulgaris</i> formation. Evaluation of hormonal and lipid abnormalities could help in treatment decisions and could affect the occurrence of complications and the course of acne.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809835/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermoscopy and reflectance confocal microscopy of metastatic Crohn's disease.","authors":"Kinga Kołcz, Elżbieta Ostańska, Ewa Kaznowska, Magdalena Żychowska","doi":"10.5114/ada.2023.133589","DOIUrl":"10.5114/ada.2023.133589","url":null,"abstract":"","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809822/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Observation of the clinical features of dupilumab-associated facial erythema.","authors":"Hao Wu, Weiming Zhang, Zhongxiao Wu, Yanna Shen, Li Zhang, Mouzhe Yang, Yougang Ren, Feng Mao","doi":"10.5114/ada.2023.132260","DOIUrl":"10.5114/ada.2023.132260","url":null,"abstract":"<p><strong>Introduction: </strong>Dupilumab is the first biologic agent used to clinically treat moderate and severe atopic dermatitis (AD) and is currently the only biologic agent used for this condition. Many studies have reported that moderate-to-severe AD was significantly improved after dupilumab injection, although head/neck dermatitis occurred with itching, flushing, and scaling. Moreover, because all the symptoms occur after dupilumab treatment, they are called \"dupilumab facial redness (DFR)\".</p><p><strong>Aim: </strong>To retrospectively analyse the clinical characteristics and treatment of facial erythema in patients with atopic dermatitis treated with dupilumab.</p><p><strong>Material and methods: </strong>The clinical data of patients with moderate-to-severe atopic dermatitis treated with dupilumab (600 mg for the first time, 300 mg every 2 weeks thereafter) in the department of dermatology from July 2020 to May 2022 were obtained. We described their characteristics and analysed their symptomatic treatment measures and efficacy.</p><p><strong>Results: </strong>Twenty-one patients with DFR were included. Most clinical manifestations were erythema and pruritus, which differed from the symptoms of typical moderate-to-severe AD. After treatment, drug withdrawal, and dressing change, the symptoms of 17 patients were effectively controlled or completely improved, while these of 4 did not improve.</p><p><strong>Conclusions: </strong>Although the mechanism of DFR is still unclear, symptomatic treatment is partially effective, and medication discontinuation and switching to Janus kinase inhibitors are acceptable for some patients.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The multiple uses of azelaic acid in dermatology: mechanism of action, preparations, and potential therapeutic applications.","authors":"Natalia Sauer, Małgorzata Oślizło, Marta Brzostek, Julianna Wolska, Katarzyna Lubaszka, Katarzyna Karłowicz-Bodalska","doi":"10.5114/ada.2023.133955","DOIUrl":"10.5114/ada.2023.133955","url":null,"abstract":"<p><p>Azelaic acid (AZA) is a naturally occurring saturated dicarboxylic acid whose topical application has found multiple uses in dermatology. Its anti-inflammatory, antioxidant and antimicrobial properties against Propionibacterium acne are currently used in the treatment of various types of acne such as rosacea and acne vulgaris. AZA is an inhibitor of tyrosinase, mitochondrial respiratory chain enzymes and DNA synthesis, and is a scavenger of harmful free radicals and inhibits the production of reactive oxygen species by neutrophils. Interestingly, AZA also has anti-proliferative and cytotoxic effects on various cancer cells. To date, its inhibitory effect on melanocytes has been mainly used, making it widely used in the treatment of hyperpigmentation disorders such as melasma and post-inflammatory hyperpigmentation. Commercially available topical formulations with cosmetic and drug status contain 5% to 20% AZA in the form of gels and creams. The use of liposomal technology allows greater control over the pharmacokinetics and pharmacodynamics of the formulations. When applied topically, AZA is well tolerated, and side effects are limited to generally mild and transient local skin irritation. Importantly, liposomal technology has enabled the drug to penetrate all layers of the skin while maintaining a very high accumulation of the active ingredient. This solution could be revolutionary for the treatment of skin cancer, where until now the main obstacle was poor absorption through the skin, making the treatment require multiple applications to maintain long-term activity levels. In this review, we will present the mechanism of action and pharmacokinetics of AZA. We will summarize its use in the treatment of dermatoses and its potential in skin cancer therapy. We will provide an overview of the preparations available on the market, taking into consideration technologies used.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between lipid parameters and the course of allergic rhinitis in children.","authors":"Agnieszka Kowalczyk, Aneta Krogulska","doi":"10.5114/ada.2023.133586","DOIUrl":"10.5114/ada.2023.133586","url":null,"abstract":"<p><strong>Introduction: </strong>A possible mechanism in the pathogenesis of allergic rhinitis (AR) is hypercholesterolemia, which may shift the balance between Th1- and Th2-dependent immune responses towards the latter.</p><p><strong>Aim: </strong>To assess the prevalence of lipid metabolism abnormalities in children with AR and their influence on the clinical course of AR.</p><p><strong>Material and methods: </strong>The study sample comprised 80 children (7-17 y.o.) with AR, including 28 with associated asthma, and 40 healthy children. Total blood cholesterol, HDL, LDL and triglyceride levels were evaluated (ARCHITECTcSystem). Skin prick tests (Allergopharma) for airborne allergens and a methacholine challenge test (Lungtest 1000, Ispa) were performed. Allergen-specific IgE for airborne allergens (Biocheck GmbH), FeNO and nNO concentrations (HypAir FeNO Medisoft) were measured.</p><p><strong>Results: </strong>Children with AR were significantly more likely to have normal HDL levels than the control group (<i>n</i> = 70; 87.5% vs. <i>n</i> = 27; 67.50%; <i>p</i> = 0.03). No significant differences were observed between these two groups regarding total cholesterol, LDL or triglyceride levels (<i>p</i> > 0.05). Abnormally high total cholesterol levels were associated with a higher risk of sensitisation to D. pteronyssinus (<i>n</i> = 18; 72%, <i>p</i> = 0.023). Children with normal levels of total cholesterol and normal triglyceride values were less likely to be sensitized to dog dander (<i>n</i> = 43; 78.18%, <i>p</i> = 0.049) (<i>n</i> = 42; 72.41%, <i>p</i> = 0.042). No significant correlations were observed between lipid parameters and the clinical course of AR, FeNO concentrations, nNO concentrations and bronchial hyperreactivity in children with AR (<i>p</i> > 0.05).</p><p><strong>Conclusions: </strong>Children with AR are as likely to demonstrate dyslipidaemia as the general population. However, the presence of lipid abnormalities in this group may increase the likelihood of sensitization to perennial allergens.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab for the treatment of moderate and severe atopic dermatitis: real-life experience.","authors":"Jowita Sroka-Tomaszewska, Barabara Bulińska, Aleksandra Wilkowska, Roman J Nowicki, Magdalena Trzeciak","doi":"10.5114/ada.2023.133818","DOIUrl":"10.5114/ada.2023.133818","url":null,"abstract":"<p><strong>Introduction: </strong>Atopic dermatitis is a relapsing, chronic, inflammatory dermatosis. So far, treatment options for more severe forms of the disease have been limited. The prospect has changed with the advent of biological drug registrations. Dupilumab is a monoclonal antibody targeting the a subunit of the IL-4 receptor and is responsible for blocking the signalling of interleukin (IL) 4 (IL-4) and IL-13. Clinical trials conducted for over 10 years have confirmed the efficacy and safety of dupilumab's treatment for atopic dermatitis.</p><p><strong>Aim: </strong>Evaluating the efficacy of dupilumab treatment in patients with moderate and severe atopic dermatitis in real life.</p><p><strong>Material and methods: </strong>We retrospectively evaluated medical records of patients treated with dupilumab for atopic dermatitis at the Department of Dermatology, Venereology and Allergology in Gdansk.</p><p><strong>Results: </strong>Ten patients in total were studied. They received dupilumab with standard dosing. The mean percentage reduction in SCORAD score was 52.16% in 8 weeks. Dupilumab was generally well tolerated and did not cause serious side effects. The most common adverse event was conjunctivitis.</p><p><strong>Conclusions: </strong>Dupilumab is an effective disease-modifying drug for patients with moderate to severe atopic dermatitis. The effects of treatment in real life are consistent with those demonstrated in clinical trials.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809831/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of upadacitinib for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis.","authors":"Yuanjie Huang, Limin Cai, Xuerui Wu, Chen Chen","doi":"10.5114/ada.2023.133820","DOIUrl":"10.5114/ada.2023.133820","url":null,"abstract":"<p><strong>Introduction: </strong>Upadacitinib, an oral selective-JAK1 inhibitor, has been used in clinical trials to treat atopic dermatitis (AD).</p><p><strong>Aim: </strong>To evaluate the efficacy and safety of upadacitinib in moderate-to-severe AD.</p><p><strong>Material and methods: </strong>We searched clinical trials from PubMed, Embase, Cochrane Library databases, and Web of Science. All randomized controlled trials (RCTs) of upadacitinib treatment on patients with moderate-to-severe AD were included. A meta-analysis was performed using the fixed- or random-effects models to calculate pooled standard mean differences or relative risks (SMD or RR, respectively).</p><p><strong>Results: </strong>Compared with the placebo group, our meta-analysis revealed that upadacitinib was related to a significant decrease in Eczema Area and Severity Index (EASI) scores, and pruritus numeric rating scale (NRS) scores. A higher response rate in Investigator's Global Assessment (IGA) and EASI-75 were also detected in the upadacitinib group. Although patients treated with upadacitinib experienced a higher incidence of adverse events (AEs), these AEs were mild and tolerated. As for serious adverse events (SAEs), there was no difference between the placebo group and the upadacitinib group.</p><p><strong>Conclusions: </strong>This meta-analysis demonstrated that upadacitinib is a safe and effective treatment for moderate-to-severe AD. Further long-term trials are required for confirmation.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of major food allergens in skincare products for atopic dermatitis.","authors":"Klaudia Ryczaj, Magdalena Chojnowska-Wójtowicz, Karolina Dumycz, Wojciech Feleszko, Marek Kulus","doi":"10.5114/ada.2023.133819","DOIUrl":"10.5114/ada.2023.133819","url":null,"abstract":"<p><strong>Introduction: </strong>Food allergy is a common concomitant disease in patients with atopic dermatitis. Sensitisation and subsequent development of food allergy might result from the application of skincare products containing food allergens, particularly when the skin barrier is impaired and inflamed. Emollients are the mainstay of the management of atopic dermatitis; however, the prevalence of food allergens in skincare products used for atopic dermatitis is unknown.</p><p><strong>Aim: </strong>To analyse the prevalence of major food allergens in skincare products for atopic dermatitis.</p><p><strong>Material and methods: </strong>Three major online cosmetic retailers in Poland were screened for atopic skincare products. The major food allergens under the mandatory allergen labelling regulation of the European Union were searched for using the INCI nomenclature of cosmetics ingredients.</p><p><strong>Results: </strong>We screened 396 skincare products, out of which 127 (32.1%) products contained at least one derivative of a major food allergen. The most common allergens were almonds, macadamia nuts, soya and cereals, followed by sesame and milk. There was no significant difference in the presence of food derivatives between leave-on and rinse-off skincare products, as well as between those intended for use by infants and children, and adults only.</p><p><strong>Conclusions: </strong>Our analysis revealed that major food allergens are prevalent in skincare products for eczema. Applying skincare products containing food derivatives on affected and inflamed skin can promote percutaneous sensitisation. Therefore, clinicians and patients with atopic dermatitis must be careful of products used for treating eczema that may contain derivatives of a major food allergen.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}